SCHEMBL3660657

SCHEMBL3660657

C/C(=N\O)c1ccccn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
ALDH1A1 P00352 2/20 0.57
TOP2A P11388 2/20 0.53
SMN1; SMN2 Q16637 7/20 0.51
RAB9A P51151 6/20 0.51
KMT2A Q03164 3/20 0.50
ALOX12 P18054 2/20 0.50
MEN1 O00255 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
GFER P55789 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 6/20 0.49
LMNA P02545 6/20 0.49
HTT P42858 3/20 0.49
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.49
HSP90AA1 P07900 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384556 1.00 KDM4E (1.00) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL1256130 0.84 KDM4E (0.73) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL167986 0.83 KDM4E (0.70) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL19386605 0.83 KDM4E (0.70) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL241401 0.83 KDM4E (0.70) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL25162057 0.81 KDM4E (0.68) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL31494657 0.81 KDM4E (0.68) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL17963025 0.81 KDM4E (0.68) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL9768928 0.81 KDM4E (0.68) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A
SCHEMBL20412779 0.80 KDM4E (0.66) KDM4EALDH1A1TOP2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US disclosed
WO-2024215809-A2 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-10-17 WO disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
EP-3548466-B1 PROCESS FOR PREPARATION OF INTERMEDIATE OF PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS SYNGENTA PARTICIPATIONS AG (CH) 2022-01-12 EP disclosed
US-10961248-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents SYNGENTA PARTICIPATIONS AG (CH) 2021-03-30 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
US-20190322675-A1 Pesticidally Active Heterocyclic Derivatives with Sulfer Containing Substituents SYNGENTA PARTICIPATIONS AG (CH) 2019-10-24 US disclosed
EP-3548466-A1 PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS Syngenta Participations AG (CH) 2019-10-09 EP disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2009-04-23 US disclosed
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2009-04-23 US disclosed
WO-2008115281-A2 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INC. (US) 2008-09-25 WO disclosed
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2008-08-28 US disclosed
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2008-08-28 US disclosed
EP-1242426-B1 GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS MERCK & CO INC (US) 2007-10-31 EP disclosed
WO-2007087204-A2 HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA SCHERING CORPOORATION (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK KDM4E 2074/4885ALDH1A1 884/4885TOP2A 3448/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 KDM4E 2853/4885ALDH1A1 656/4885TOP2A 3485/4885
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 KDM4E 3380/4885ALDH1A1 933/4885TOP2A 1655/4885
US-10961248-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents DDT, ACHE, SQOR KDM4E 3259/4885ALDH1A1 616/4885TOP2A 1290/4885
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR KDM4E 1834/4885ALDH1A1 4593/4885TOP2A 3398/4885
US-20190322675-A1 Pesticidally Active Heterocyclic Derivatives with Sulfer Containing Substituents DDT, ACHE, SQOR KDM4E 2587/4885ALDH1A1 568/4885TOP2A 1258/4885
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 KDM4E 3380/4885ALDH1A1 933/4885TOP2A 1655/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 KDM4E 2853/4885ALDH1A1 656/4885TOP2A 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.